Dr. Myriam Chalabi, an oncologist at Netherlands Cancer Institute, spoke with the Oncology Brothers (Drs. Rohit and Rahul Gosain) to discuss the NICHE-2 study, which assessed the use of neoadjuvant immunotherapy in deficient mismatch repair (dMMR) colon cancer. In this study consisting of 112 patients, adjuvant immunotherapy yielded highly robust pathologic responses in 100% of dMMR tumors, indicating the strong potential for adjuvant immunotherapy to become standard of care.
Advertisement
Advertisement